AviadoBio broadens vMiX gene silencing licence with King’s College London

AviadoBio has extended its exclusive licence agreement with King’s College London to apply the vMiX RNAi gene-silencing platform across all human therapeutic areas. The expanded licensing lets AviadoBio pursue partnerships for broader applications, including cardiovascular, nephrology, oncology, and beyond the CNS. The vMiX platform leverages AAV as a delivery vector and harnesses the cell’s natural RNA interference process. Credit: angellodeco / Shutterstock.com. AviadoBio has extended its exclusive licence agreement with King’s College London to apply the vMiX ribonucleic acid interference (RNAi) gene-silencing platform across all human therapeutic areas. The agreement broadens AviadoBio’s existing rights, which were previously limited to the…

Source: Pharmaceutical Technology